Pipeline

The current pipeline of OncoBone Ventures includes four therapeutic assets that are co-developed with original inventors of the assets. In addition, several potential assets are under evaluation.

Click the to find out more about the therapeutic asset of each partner

Indication
Therapeutic asset
Discovery In vitro In vivo-efficacy In vivo-safety Clinical Trials Regulatory approval
Bone predominant TNBC
OBP-001 Humanised antibody
Outlicense for clinical development estimated in 2027

OBP-001 is a first-in-class humanized immunomodulating antibody that has provided proof-of-concept for inhibiting breast cancer lung metastasis. OncoBone Ventures will study proof-of-concept for bone metastasis, followed by regulatory safety studies and finding an outlicensing partner for the asset.

Bone metastatic CRPC
OBP-002 Small molecule inhibitor
Outlicense for clinical development estimated in 2028

OBP-002 is a first-in-class small molecule enzyme inhibitor with good pharmacological profile. Proof-of-concept studies are to be conducted, followed by regulatory safety studies and finding an outlicensing partner for the asset.

Bone metastatic cancers
OBP-003 Humanized antibody
Outlicence for clinical development estimated in 2028

OBP-003 is a humanized antibody for a target that is an important regulator of tumor immune escape. Proof-of-concept studies for bone metastasis are to be conducted, followed by regulatory safety studies and finding outlicensing partner for the asset.

TNBC, Multiple myeloma
OBP-004 Small molecule inhibitor
Outlicense for clinical development estimated in 2027

OBP-004 is a small-molecule inhibitor that has demonstrated preliminary efficacy for bone metastases in a preclinical study. Proof-of-concept studies for bone metastasis are to be conducted, followed by regulatory safety studies and finding outlicensing partner for the asset.